{"id":62904,"date":"2026-04-12T11:38:48","date_gmt":"2026-04-12T03:38:48","guid":{"rendered":"https:\/\/flcube.com\/?p=62904"},"modified":"2026-04-12T11:38:49","modified_gmt":"2026-04-12T03:38:49","slug":"gilead-exercises-option-on-kymeras-kt-200-for-45m-advances-cdk2-molecular-glue-degrader-to-ind-enabling-studies","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=62904","title":{"rendered":"Gilead Exercises Option on Kymera&#8217;s KT-200 for $45M \u2013 Advances CDK2 Molecular Glue Degrader to IND-Enabling Studies"},"content":{"rendered":"\n<p><strong>Kymera Therapeutics, Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/KYMR:NASDAQ\">NASDAQ:\u202fKYMR<\/a>) announced that partner <strong>Gilead Sciences Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/GILD:NASDAQ\">NASDAQ:\u202fGILD<\/a>) has <strong>exercised its exclusive global license option<\/strong> for <strong>KT-200<\/strong>, a <strong>novel molecular glue degrader (MGD)<\/strong> targeting <strong>cyclin-dependent kinase 2 (CDK2)<\/strong>. Kymera will receive a <strong>US$45\u202fmillion milestone payment<\/strong>, with Gilead advancing the program into <strong>IND-enabling studies<\/strong> to support a <strong>2027 IND submission<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-transaction-overview\">Transaction Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Milestone Payment<\/strong><\/td><td><strong>US$45\u202fmillion<\/strong> (option exercise fee)<\/td><\/tr><tr><td><strong>Next Steps<\/strong><\/td><td>IND-enabling studies; IND submission targeted <strong>2027<\/strong><\/td><\/tr><tr><td><strong>Licensed Rights<\/strong><\/td><td>Exclusive <strong>global<\/strong> development and commercialization<\/td><\/tr><tr><td><strong>Original Deal<\/strong><\/td><td><strong>US$750\u202fmillion<\/strong> total potential value (June\u202f2025)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-original-partnership-terms-june-2025\">Original Partnership Terms (June\u202f2025)<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Element<\/th><th>Value<\/th><\/tr><\/thead><tbody><tr><td><strong>Upfront + Option Fees<\/strong><\/td><td>Up to <strong>US$85\u202fmillion<\/strong><\/td><\/tr><tr><td><strong>Development\/Commercial Milestones<\/strong><\/td><td>Balance of <strong>US$750\u202fmillion<\/strong> total deal value<\/td><\/tr><tr><td><strong>Royalties<\/strong><\/td><td><strong>High\u2011single\u2011digit to mid\u2011teen<\/strong> percentages on net sales<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism-of-action\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> <strong>KT-200<\/strong> \u2013 <strong>Molecular Glue Degrader (MGD)<\/strong><\/li>\n\n\n\n<li><strong>Target:<\/strong> <strong>CDK2<\/strong> (cyclin\u2011dependent kinase 2) \u2013 Cell cycle regulator overexpressed in multiple cancers<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Induces proximity between CDK2 and E3 ubiquitin ligase, leading to <strong>targeted protein degradation<\/strong><\/li>\n\n\n\n<li><strong>Advantage:<\/strong> Degrader approach eliminates <strong>scaffold functions<\/strong> of CDK2, potentially superior to catalytic inhibition<\/li>\n\n\n\n<li><strong>Indications:<\/strong> Under evaluation for <strong>CDK2\u2011dependent tumors<\/strong>, including ovarian, endometrial, and breast cancer subsets<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Kymera Therapeutics:<\/strong><\/li>\n\n\n\n<li><strong>US$45\u202fmillion non\u2011dilutive capital<\/strong> strengthens balance sheet<\/li>\n\n\n\n<li>Validation of <strong>Pegasus\u2122 targeted protein degradation platform<\/strong><\/li>\n\n\n\n<li>Retains <strong>co\u2011development\/co\u2011promotion rights<\/strong> for certain indications (per original agreement)<\/li>\n\n\n\n<li><strong>Gilead Sciences:<\/strong><\/li>\n\n\n\n<li>Expands <strong>oncology pipeline<\/strong> beyond cell therapy and antibody\u2011drug conjugates<\/li>\n\n\n\n<li>CDK2 degrader complements existing <strong>CDK4\/6 inhibitor<\/strong> portfolio (trilaciclib)<\/li>\n\n\n\n<li>Leverages Kymera&#8217;s degrader expertise while retaining full global commercial control<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-outlook\">Market Context &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Targeted Protein Degradation Market:<\/strong> Projected <strong>US$15\u201120\u202fbillion<\/strong> by 2035; molecular glues represent next\u2011generation modality beyond PROTACs<\/li>\n\n\n\n<li><strong>CDK2 Opportunity:<\/strong> <strong>~30% of high\u2011grade serous ovarian cancers<\/strong> exhibit CDK2 dependency; addressable market <strong>US$3\u20115\u202fbillion<\/strong> across solid tumor indications<\/li>\n\n\n\n<li><strong>Competitive Landscape:<\/strong><\/li>\n\n\n\n<li><strong>Nurix \/ Sanofi<\/strong> \u2013 CDK2 degrader programs in preclinical\/early clinical<\/li>\n\n\n\n<li><strong>C4 Therapeutics<\/strong> \u2013 CFT\u20112719 (CDK2 degrader) in IND\u2011enabling studies<\/li>\n\n\n\n<li><strong>Kymera \/ Gilead<\/strong> \u2013 <strong>First major pharma\u2011backed CDK2 MGD<\/strong> with clear regulatory timeline<\/li>\n\n\n\n<li><strong>Valuation Impact:<\/strong> Option exercise validates platform; Kymera shares expected to react positively to de\u2011risking milestone<\/li>\n\n\n\n<li><strong>Clinical Timeline:<\/strong> Phase\u202fI initiation projected <strong>2028<\/strong> pending successful IND; proof\u2011of\u2011concept data <strong>2029\u20112030<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding milestone payments, regulatory timelines, and clinical development for KT-200. Actual results may differ due to risks including IND rejection, safety findings, competitive advances, and Gilead&#8217;s portfolio prioritization decisions.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Kymera Therapeutics, Inc. (NASDAQ:\u202fKYMR) announced that partner Gilead Sciences Inc. (NASDAQ:\u202fGILD) has exercised its exclusive&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[226,548,1025,1269,70],"class_list":["post-62904","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-gilead-sciences","tag-kymera-therapeutics","tag-nasdaq-gild","tag-nasdaq-kymr","tag-tpd"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Gilead Exercises Option on Kymera&#039;s KT-200 for $45M \u2013 Advances CDK2 Molecular Glue Degrader to IND-Enabling Studies - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Kymera Therapeutics, Inc. (NASDAQ:\u202fKYMR) announced that partner Gilead Sciences Inc. (NASDAQ:\u202fGILD) has exercised its exclusive global license option for KT-200, a novel molecular glue degrader (MGD) targeting cyclin-dependent kinase 2 (CDK2). Kymera will receive a US$45\u202fmillion milestone payment, with Gilead advancing the program into IND-enabling studies to support a 2027 IND submission.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=62904\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Gilead Exercises Option on Kymera&#039;s KT-200 for $45M \u2013 Advances CDK2 Molecular Glue Degrader to IND-Enabling Studies\" \/>\n<meta property=\"og:description\" content=\"Kymera Therapeutics, Inc. (NASDAQ:\u202fKYMR) announced that partner Gilead Sciences Inc. (NASDAQ:\u202fGILD) has exercised its exclusive global license option for KT-200, a novel molecular glue degrader (MGD) targeting cyclin-dependent kinase 2 (CDK2). Kymera will receive a US$45\u202fmillion milestone payment, with Gilead advancing the program into IND-enabling studies to support a 2027 IND submission.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=62904\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-12T03:38:48+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-12T03:38:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62904#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62904\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Gilead Exercises Option on Kymera&#8217;s KT-200 for $45M \u2013 Advances CDK2 Molecular Glue Degrader to IND-Enabling Studies\",\"datePublished\":\"2026-04-12T03:38:48+00:00\",\"dateModified\":\"2026-04-12T03:38:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62904\"},\"wordCount\":407,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Gilead Sciences\",\"Kymera Therapeutics\",\"NASDAQ: GILD\",\"NASDAQ: KYMR\",\"TPD\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62904#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62904\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=62904\",\"name\":\"Gilead Exercises Option on Kymera's KT-200 for $45M \u2013 Advances CDK2 Molecular Glue Degrader to IND-Enabling Studies - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-04-12T03:38:48+00:00\",\"dateModified\":\"2026-04-12T03:38:49+00:00\",\"description\":\"Kymera Therapeutics, Inc. (NASDAQ:\u202fKYMR) announced that partner Gilead Sciences Inc. (NASDAQ:\u202fGILD) has exercised its exclusive global license option for KT-200, a novel molecular glue degrader (MGD) targeting cyclin-dependent kinase 2 (CDK2). Kymera will receive a US$45\u202fmillion milestone payment, with Gilead advancing the program into IND-enabling studies to support a 2027 IND submission.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62904#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62904\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62904#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Gilead Exercises Option on Kymera&#8217;s KT-200 for $45M \u2013 Advances CDK2 Molecular Glue Degrader to IND-Enabling Studies\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Gilead Exercises Option on Kymera's KT-200 for $45M \u2013 Advances CDK2 Molecular Glue Degrader to IND-Enabling Studies - Insight, China&#039;s Pharmaceutical Industry","description":"Kymera Therapeutics, Inc. (NASDAQ:\u202fKYMR) announced that partner Gilead Sciences Inc. (NASDAQ:\u202fGILD) has exercised its exclusive global license option for KT-200, a novel molecular glue degrader (MGD) targeting cyclin-dependent kinase 2 (CDK2). Kymera will receive a US$45\u202fmillion milestone payment, with Gilead advancing the program into IND-enabling studies to support a 2027 IND submission.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=62904","og_locale":"en_US","og_type":"article","og_title":"Gilead Exercises Option on Kymera's KT-200 for $45M \u2013 Advances CDK2 Molecular Glue Degrader to IND-Enabling Studies","og_description":"Kymera Therapeutics, Inc. (NASDAQ:\u202fKYMR) announced that partner Gilead Sciences Inc. (NASDAQ:\u202fGILD) has exercised its exclusive global license option for KT-200, a novel molecular glue degrader (MGD) targeting cyclin-dependent kinase 2 (CDK2). Kymera will receive a US$45\u202fmillion milestone payment, with Gilead advancing the program into IND-enabling studies to support a 2027 IND submission.","og_url":"https:\/\/flcube.com\/?p=62904","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-12T03:38:48+00:00","article_modified_time":"2026-04-12T03:38:49+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=62904#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=62904"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Gilead Exercises Option on Kymera&#8217;s KT-200 for $45M \u2013 Advances CDK2 Molecular Glue Degrader to IND-Enabling Studies","datePublished":"2026-04-12T03:38:48+00:00","dateModified":"2026-04-12T03:38:49+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=62904"},"wordCount":407,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Gilead Sciences","Kymera Therapeutics","NASDAQ: GILD","NASDAQ: KYMR","TPD"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=62904#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=62904","url":"https:\/\/flcube.com\/?p=62904","name":"Gilead Exercises Option on Kymera's KT-200 for $45M \u2013 Advances CDK2 Molecular Glue Degrader to IND-Enabling Studies - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-04-12T03:38:48+00:00","dateModified":"2026-04-12T03:38:49+00:00","description":"Kymera Therapeutics, Inc. (NASDAQ:\u202fKYMR) announced that partner Gilead Sciences Inc. (NASDAQ:\u202fGILD) has exercised its exclusive global license option for KT-200, a novel molecular glue degrader (MGD) targeting cyclin-dependent kinase 2 (CDK2). Kymera will receive a US$45\u202fmillion milestone payment, with Gilead advancing the program into IND-enabling studies to support a 2027 IND submission.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=62904#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=62904"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=62904#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Gilead Exercises Option on Kymera&#8217;s KT-200 for $45M \u2013 Advances CDK2 Molecular Glue Degrader to IND-Enabling Studies"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62904","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=62904"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62904\/revisions"}],"predecessor-version":[{"id":62905,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62904\/revisions\/62905"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=62904"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=62904"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=62904"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}